Who owns Lakefront Biotherapeutics NV (GLPG)? Elite investor 13F holders
3 tracked elite investors reported holding Lakefront Biotherapeutics NV as of 2026-06-30, including Greenlight Capital, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Greenlight Capital | GALAPAGOS NV | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 14472725.00 USD | 482746.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | GALAPAGOS NV | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 12225844.00 USD | 407800.000000 | Shares | add | Original filing |
| D.E. Shaw | GALAPAGOS NV | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 5931363.00 USD | 197844.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.